$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo

$abeo Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000114420418058739 Filed on November 09, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2018 Q2
Revenue	$480.0K	$1.709M	$819.0K
YoY Change	118.18%	680.37%	277.42%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.630M	$4.970M	$4.630M
YoY Change	145.34%	129.03%	75.38%
% of Gross Profit
Research & Development	$9.470M	$13.15M	$7.916M
YoY Change	65.97%	301.28%	36.29%
% of Gross Profit
Depreciation & Amortization	$1.390M	$505.0K	$290.0K
YoY Change	892.86%	265.94%	40.1%
% of Gross Profit
Operating Expenses	$9.470M	$13.15M	$7.916M
YoY Change	65.97%	301.28%	36.29%
Operating Profit	-$18.01M	-$16.92M	-$12.56M
YoY Change	105.83%	215.48%	48.78%
Interest Expense	$530.0K	$500.0K	$310.0K
YoY Change	76.67%	2400.0%	93.75%
% of Operating Profit
Other Income/Expense, Net		$497.0K	$314.0K
YoY Change		2515.79%	95.03%
Pretax Income	-$17.48M	-$16.42M	-$12.24M
YoY Change	106.86%	207.49%	47.83%
Income Tax
% Of Pretax Income
Net Earnings	-$17.48M	-$16.42M	-$12.24M
YoY Change	106.85%	207.3%	47.88%
Net Earnings / Revenue	-3641.46%	-960.74%	-1494.87%
Basic Earnings Per Share
Diluted Earnings Per Share	-$360.6K	-$339.8K	-$258.8K
COMMON SHARES
Basic Shares Outstanding	47.94M shares	47.94M shares	47.31M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$85.00M	$112.2M	$119.8M
YoY Change	-38.32%	98.58%	105.49%
Cash & Equivalents	$18.75M	$33.60M	$49.99M
Short-Term Investments	$66.20M	$78.60M	$69.90M
Other Short-Term Assets	$3.800M	$2.000M	$1.900M
YoY Change	40.74%	11.11%	111.11%
Inventory
Prepaid Expenses
Receivables	$100.0K	$400.0K	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$88.85M	$114.6M	$121.8M
YoY Change	-36.8%	96.15%	105.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.443M	$9.245M	$8.007M
YoY Change	587.26%	1220.71%	1043.86%
Goodwill	$32.47M	$32.47M	$32.47M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$600.0K	$600.0K	$600.0K
YoY Change	50.0%	500.0%	500.0%
Total Long-Term Assets	$85.55M	$46.03M	$44.87M
YoY Change	124.1%	23.39%	20.11%
TOTAL ASSETS
Total Short-Term Assets	$88.85M	$114.6M	$121.8M
Total Long-Term Assets	$85.55M	$46.03M	$44.87M
Total Assets	$174.4M	$160.6M	$166.7M
YoY Change	-2.44%	67.79%	72.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.122M	$10.33M	$5.783M
YoY Change	225.47%	416.55%	59.88%
Accrued Expenses	$3.936M
YoY Change	668.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$20.35M	$10.33M	$5.783M
YoY Change	263.01%	297.35%	37.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$20.00M	$0.00	$0.00
YoY Change	545.16%	-100.0%	-100.0%
Total Long-Term Liabilities	$20.00M	$0.00	$0.00
YoY Change	545.16%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.35M	$10.33M	$5.783M
Total Long-Term Liabilities	$20.00M	$0.00	$0.00
Total Liabilities	$40.35M	$10.33M	$5.783M
YoY Change	365.55%	75.1%	-23.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$410.2M	-$392.7M	-$376.3M
YoY Change	14.01%		8.76%
Common Stock	$544.2M	$543.0M	$537.2M
YoY Change	2.71%		23.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$134.0M	$150.2M	$160.9M
YoY Change
Total Liabilities & Shareholders Equity	$174.4M	$160.6M	$166.7M
YoY Change	-2.44%	67.79%	72.46%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2018 Q2
OPERATING ACTIVITIES
Net Income	-$17.48M	-$16.42M	-$12.24M
YoY Change	106.85%	207.3%	47.88%
Depreciation, Depletion And Amortization	$1.390M	$505.0K	$290.0K
YoY Change	892.86%	265.94%	40.1%
Cash From Operating Activities	-$16.97M	-$9.040M	-$9.020M
YoY Change	236.04%	33.53%	81.12%
INVESTING ACTIVITIES
Capital Expenditures	-$10.91M	-$1.660M	-$3.420M
YoY Change	1458.57%	1975.0%	34100.0%
Acquisitions
YoY Change
Other Investing Activities	$13.04M	-$8.780M	-$69.85M
YoY Change
Cash From Investing Activities	$2.120M	-$10.43M	-$73.28M
YoY Change	-402.86%	12937.5%	732700.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	3.080M	570.0K
YoY Change	-100.0%	-39.13%	533.33%
NET CHANGE
Cash From Operating Activities	-16.97M	-9.040M	-9.020M
Cash From Investing Activities	2.120M	-10.43M	-73.28M
Cash From Financing Activities	0.000	3.080M	570.0K
Net Change In Cash	-14.85M	-16.39M	-81.73M
YoY Change	-118.22%	815.64%	1567.96%
FREE CASH FLOW
Cash From Operating Activities	-$16.97M	-$9.040M	-$9.020M
Capital Expenditures	-$10.91M	-$1.660M	-$3.420M
Free Cash Flow	-$6.060M	-$7.380M	-$5.600M
YoY Change	39.31%	10.31%	12.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	ABEONA THERAPEUTICS INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0000318306
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	ABEO
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47944486	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33599000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137750000	USD
CY2018Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	352000	USD
CY2017Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	107000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1975000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2735000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	114551000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	140592000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-359792000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	150245000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	173761000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9245000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1374000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3717000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3977000	USD
CY2018Q3	us-gaap	Goodwill Goodwill	32466000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	32466000	USD
CY2018Q3	abeo	Other Assets And Restricted Cash OtherAssetsAndRestrictedCash	597000	USD
CY2017Q4	abeo	Other Assets And Restricted Cash OtherAssetsAndRestrictedCash	357000	USD
CY2018Q3	us-gaap	Assets Assets	160576000	USD
CY2017Q4	us-gaap	Assets Assets	178766000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	10331000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2393000	USD
CY2018Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3214000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	10331000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5607000	USD
CY2018Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3061000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	10331000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	8668000	USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	480000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	469000	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	542476000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	529421000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-392711000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	160576000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	178766000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2612000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2612000	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2018Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2018Q1	us-gaap	Liabilities Liabilities	5005000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-356129000	USD
CY2018Q3	abeo	Revenue Revenue	1709000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
	abeo	Revenue Revenue	5126000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
CY2018Q3	us-gaap	Grants Receivable GrantsReceivable	13850000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1600000	USD
CY2018Q3	abeo	Proceeds From Grant Received ProceedsFromGrantReceived	5000000	USD
CY2017Q4	abeo	Proceeds From Grant Received ProceedsFromGrantReceived	2600000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	560000	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2018Q3	us-gaap	Revenues Revenues	1709000	USD
CY2017Q3	us-gaap	Revenues Revenues	219000	USD
	us-gaap	Revenues Revenues	5126000	USD
	us-gaap	Revenues Revenues	622000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13150000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3277000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29228000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11283000	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4970000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2166000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12475000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7830000	USD
CY2018Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	505000	USD
CY2017Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	138000	USD
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	18625000	USD
CY2017Q3	us-gaap	Costs And Expenses CostsAndExpenses	5581000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	42672000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	19708000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-16916000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5362000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-37546000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19086000	USD
CY2018Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	500000	USD
CY2017Q3	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	21000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	973000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	224000	USD
CY2018Q3	abeo	Interest And Other Expense InterestAndOtherExpense	3000	USD
CY2017Q3	abeo	Interest And Other Expense InterestAndOtherExpense	2000	USD
	abeo	Interest And Other Expense InterestAndOtherExpense	9000	USD
	abeo	Interest And Other Expense InterestAndOtherExpense	7000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	964000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	217000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	260000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	448000	USD
CY2017Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	87000	USD
CY2018Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	87000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	86000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	346000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	346000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	346000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	346000	USD
CY2018Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2247000	USD
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.09	pure
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0278	pure
CY2018Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.44
CY2018Q3	abeo	Sharebased Compensation Arrangement By Sharebased Payment Award Option Grants In Period Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantsInPeriodWeightedAverageGrantDateFairValue	11.44	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.09	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0254	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.36
	abeo	Sharebased Compensation Arrangement By Sharebased Payment Award Option Grants In Period Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionGrantsInPeriodWeightedAverageGrantDateFairValue	11.36	USD
CY2018Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	78625000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	497000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	19000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-16419000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-5343000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-36582000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47794394	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40377890	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	47388833	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40301601	shares
	us-gaap	Net Income Loss NetIncomeLoss	-18869000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	969000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	595000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7072000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3527000	USD
	abeo	Allocated Share Based Compensation Expense Restricted Stock AllocatedShareBasedCompensationExpenseRestrictedStock	516000	USD
	abeo	Allocated Share Based Compensation Expense Restricted Stock AllocatedShareBasedCompensationExpenseRestrictedStock	979000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	245000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-13000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-760000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1607000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7938000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1657000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2612000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-452000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22144000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17609000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8580000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	156000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-87205000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-156000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2245000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	93000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5478000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5145000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-103871000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12620000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	138030000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	69142000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34159000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	56522000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56522000	USD
	us-gaap	Interest Paid Net InterestPaidNet	9000	USD
	us-gaap	Interest Paid Net InterestPaidNet	7000	USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	USD
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	127000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	94991000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	4000000	USD
	abeo	Cash And Cash Equivalents Restricted Cash CashAndCashEquivalentsRestrictedCash	34159000	USD
	abeo	Cash And Cash Equivalents Restricted Cash CashAndCashEquivalentsRestrictedCash	56522000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-40000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	11000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	78625000	USD
CY2018Q3	abeo	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice	14.45
	abeo	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExercisePrice	14.38
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47944486	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46888108	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	170098000	USD
CY2018Q1	us-gaap	Cumulative Effect On Retained Earnings Net Of Tax1 CumulativeEffectOnRetainedEarningsNetOfTax1	3663000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1900000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	172000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1685000	USD
CY2018Q1	abeo	Stock Issued During Period Value Warrants Two Exercised StockIssuedDuringPeriodValueWarrantsTwoExercised	144000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-8463000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	169199000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2673000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	172000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	481000	USD
CY2018Q2	abeo	Stock Issued During Period Value Warrants Two Exercised StockIssuedDuringPeriodValueWarrantsTwoExercised	89000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-11700000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	160914000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2499000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	172000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	79000	USD
CY2018Q3	abeo	Stock Issued During Period Value Warrants Two Exercised StockIssuedDuringPeriodValueWarrantsTwoExercised	3000000	USD
CY2017	abeo	Proceeds From Grant Received ProceedsFromGrantReceived	2.4	USD
CY2018Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	800000	USD
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	16366000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	0	USD

Files In Submission

Name	View Source	Status
0001144204-18-058739-index-headers.html	Edgar Link	pending
0001144204-18-058739-index.html	Edgar Link	pending
0001144204-18-058739.txt	Edgar Link	pending
0001144204-18-058739-xbrl.zip	Edgar Link	pending
abeo-20180930.xml	Edgar Link	completed
abeo-20180930.xsd	Edgar Link	pending
abeo-20180930_cal.xml	Edgar Link	unprocessable
abeo-20180930_def.xml	Edgar Link	unprocessable
abeo-20180930_lab.xml	Edgar Link	unprocessable
abeo-20180930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv506017_10q.htm	Edgar Link	pending
tv506017_ex31-1.htm	Edgar Link	pending
tv506017_ex31-2.htm	Edgar Link	pending
tv506017_ex32-1.htm	Edgar Link	pending
tv506017_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo

2018 Q4 Form 10-Q Financial Statement

#000114420418058739 Filed on November 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABEO ABEONA THERAPEUTICS INC. Stock $abeo

2018 Q4 Form 10-Q Financial Statement

#000114420418058739 Filed on November 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo